Esmolol

  • Brevibloc
  • Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester
Formula
C16H25NO4
Structure
Description
Clear, colorless to slightly yellow solution with a distinctive alcohol odor.
Uses
Medication.

Registry Numbers and Inventories.
CAS
103598-03-4
Beilstein/Gmelin
5287174

Properties.
Formula
C16H25NO4
Formula mass
295.38
Melting point, °C
48 - 50
Density
1.026 g/cm3 (20 C)
Solubility in water
Slightly soluble
pKa/pKb
4.83 (pKb)

Hazards and Protection.
Storage
Store at room temperature in a dark location. Keep containers closed.
Handling
Do not consume food or drink in the area. Use good housekeeping procedures.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use air purifying respirator or air supplied respirator if necessary.
Small spills/leaks
Use appropriate protective equipment during cleanup. No special procedures are required for small spills.
Stability
Stable at normal temperatures and pressures.
Incompatibilities
Strong oxidizing agents.
Decomposition
None reported.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
Low heart rate and abnormally low blood pressure are common. Respiratory depression may occur with severe poisoning. fatigue, sleepiness, headache, sedation and confusion may develop with therapeutic use. CNS depression, coma and seizures may develop in overdose.
   Ingestion
Nausea and vomiting may be noted. Mesenteric ischemia has been reported as a sequelae of overdose.
   Inhalation
Increased airway resistance, wheezing, pulmonary edema, cyanosis, respiratory depression may develop. In severe cases respiratory arrest may occur.
   Skin
Irritation.
   Eyes
Diplopia and eye irritation may develop with therapeutic use. Mydriasis has been reported overdose.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Transport.